Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

furmonertinib 240 mg oral, daily - Phase 3 | AVBP Pipeline | CatalystAlert

furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma, Inc. (AVBP)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Metastatic Non-Small Cell Lung Cancer

Clinical Trial

Last updated: 12/4/2025

Developer

AVBP

ArriVent BioPharma, Inc.

Biotechnology•North America•NASDAQ